{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05812274",
            "orgStudyIdInfo": {
                "id": "AAAU2705"
            },
            "organization": {
                "fullName": "Columbia University",
                "class": "OTHER"
            },
            "briefTitle": "Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients",
            "officialTitle": "A Phase IV Study of Apricity C.A.R.E. Program for Cancer Adverse Events Rapid Evaluation to Improve Treatment Outcomes of Ethnic/Racial Minority Non-small Cell Lung Cancer (NSCLC) Patients Receiving Immunotherapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "apricity-care-to-improve-ici-outcomes-of-ethnic-racial-minority-nsclc-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-30",
            "studyFirstSubmitQcDate": "2023-03-31",
            "studyFirstPostDateStruct": {
                "date": "2023-04-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-03-31",
            "lastUpdatePostDateStruct": {
                "date": "2023-04-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Brian Henick, MD",
                "investigatorTitle": "Assistant Professor of Medicine at the Columbia University Medical Center",
                "investigatorAffiliation": "Columbia University"
            },
            "leadSponsor": {
                "name": "Columbia University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this trial is to study the effectiveness of the AprictyRxTM care service to improve treatment outcomes of ethnic/racial minority N.S.C.L.C. patients receiving standard of care immunotherapy, and reduce the frequency of healthcare system interactions.",
            "detailedDescription": "Immune checkpoint inhibitors (I.C.I.) targeting the PD-1/PD-L1 axis have changed the treatment landscape of non-small cell lung cancer (N.S.C.L.C.). After demonstrating improved efficacy and tolerability compared to standard chemotherapy in several large clinical trials, these novel drugs are now F.D.A. approved in multiple treatment settings. With the increase in I.C.I. use, the incidence of immune-related adverse effects (irAEs) has also risen, occurring in up to 16% of ICI-treated patients. Prompt recognition and timely management are necessary to avert potential poor outcomes from direct toxicity and/or early treatment discontinuation. However, rapid adoption of I.C.I.s may limit healthcare providers' experience and comfort with managing important irAEs. Additionally, existing barriers to access care that disproportionately impact racial and ethnic minority patients may amplify the inability to manage patients on I.C.I.s effectively.\n\nUsing technologically-enabled health interventions in a culturally competent manner can improve access to health care resources and reduce health disparities. These platforms need to be optimized at the literacy level of underserved minority communities and can be adapted to meet the community's needs. Recently, technology-enabled services focused on patient-reported outcomes have garnered growing interest in oncology."
        },
        "conditionsModule": {
            "conditions": [
                "Non Small Cell Lung Cancer"
            ],
            "keywords": [
                "Non Small Cell Lung Cancer",
                "Immune-Checkpoint Inhibitor"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "People who meet eligibility requirements and provide informed consent will be randomly allocated to the two arms with a 1:1 allocation ratio.The randomization will match patients according to: 1) age, 2) performance status (ECOG \\<2 vs \\>=2) and 3) receiving ICI monotherapy vs. ICI plus chemotherapy.",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 280,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intervention Arm",
                    "type": "EXPERIMENTAL",
                    "description": "Participants are provided with ApricityRx digital solution with pulse oximeters and 24/7 C.A.R.E. (Cancer Adverse event Rapid Evaluation) to monitor and capture ePRO, identify onset or progression of symptoms verified by nurse triage, trigger intervention by the study team.",
                    "interventionNames": [
                        "Other: Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation"
                    ]
                },
                {
                    "label": "Control Arm",
                    "type": "NO_INTERVENTION",
                    "description": "Clinicians will monitor NSCLC patients on ICIs for irAEs as a standard of care using routine practices."
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Apricity C.A.R.E. Program for Cancer Adverse events Rapid Evaluation",
                    "description": "The Apricity CARE program for Cancer Adverse events Rapid Evaluation is a cloud-based 24/7 on-demand clinical coverage service, delivered exclusively via the ApricityRx digital care platform by certified and licensed healthcare professionals who are trained to monitor patient's symptoms and conduct standardized triage following guideline-based or protocol-specified pathways with 3 parts:\n\n* ApricityCare\u2122 Mobile Application - to collect health data (PGHD) on biometrics and self-reported symptoms (PRO) of symptoms and potential side effects at home, in between doctors' visits, and offers educational content in video.\n* ApricityOncology\u2122 Web-based Application - to provide authorized healthcare providers an organized, longitudinal and summarized view of a patient's pertinent cancer history and real world PGHD for purpose of symptom monitoring.\n* ApricityManage\u2122 Dashboard - a dashboard intended for administrators, sponsors or funders to track program status.",
                    "armGroupLabels": [
                        "Intervention Arm"
                    ],
                    "otherNames": [
                        "Apricity CARE program"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean Likert-type scale score",
                    "description": "Two focus group discussions (FGDs), stratified on a Likert-type scale based on the frequency of utilization, to determine factors related to usage of ApricityCare app and utilization of the CARE monitoring service (Run-in phase). To assess factors related to suboptimal and optimal use of the ApricityCare app and the CARE monitoring service, collectively \"the Apricity CARE program\".",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Percent of study patients who experienced treatment delay/discontinuation",
                    "description": "To determine the impact of the the Apricity CARE program on immunotherapy toxicity monitoring for N.S.C.L.C. patients receiving immunotherapy in a highly diverse New York City community. Immune Checkpoint Inhibitor (ICI) treatment delay or discontinuation is defined as a gap between doses of ICI beyond 60 days and/or the initiation of another cancer therapy without evidence of disease progression.",
                    "timeFrame": "2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percent of study patients who experience a severe irAE (grade 3 or higher).",
                    "description": "To assess the percent of study patients who experience a severe irAE (grade 3 or higher) while on study. Information about individual treatment toxicities (i.e., type, frequency) will be obtained and recorded from the ApricityRxTM platform and patient's clinical note. Toxicity grade will be assigned using the NCI CTCAE v5.0 and tallied.",
                    "timeFrame": "2.5 years"
                },
                {
                    "measure": "Time to irAE management",
                    "description": "To quantify time to irAE management with ICI. This will be defined as the time from the onset of irAE to time of active intervention (i.e., change in administration schedule, new prescription of supportive medication, telephone counseling about symptoms, unscheduled visits or referrals). Information will be obtained and recorded from the ApricityRxTM platform and patient's clinical note, and tallied. Unit measured in days.",
                    "timeFrame": "2.5 years"
                },
                {
                    "measure": "Time to treatment discontinuation with ICI",
                    "description": "To quantify time to irAE management with ICI. This will be determined as starting date of ICI to date of the last dose of ICI for any reason specified by patient's EMR. Information will be obtained and recorded from the ApricityRxTM platform and patient's clinical note, and tallied. Unit measured in days.",
                    "timeFrame": "2.5 years"
                },
                {
                    "measure": "Number of interactions with the care team and utilization",
                    "description": "This will be quantified as the number of clinical interactions between patients and providers from the patient's EMR and will include telephone encounters, unscheduled clinic visits, ED visits, hospital admissions - total will be tallied.",
                    "timeFrame": "2.5 years"
                },
                {
                    "measure": "Number of interviews/surveys completed",
                    "description": "Patient and provider experience will be assessed with focus group discussions (FGDs), semi-structured interviews, and surveys",
                    "timeFrame": "2.5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age\u2265 18 years\n* Confirmed NSCLC diagnosis\n* Prescribed treatment with immune-checkpoint inhibitor, including in combination with chemotherapy\n* Ability to understand and the willingness to sign a written informed consent document\n* Self-identification as a member of an ethnic minority or underserved population.\n\nExclusion Criteria:\n\n* An individual with presence of any medical, psychological, or social condition that, in the opinion of the investigator would preclude participation in this study.\n* Patients enrolled in other interventional clinical trials at the time of screening will be excluded.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Brian Henick, MD",
                    "role": "CONTACT",
                    "phone": "212-305-3997",
                    "email": "bh2682@cumc.columbia.edu"
                },
                {
                    "name": "Research Nurse Navigator",
                    "role": "CONTACT",
                    "phone": "212-342-5162",
                    "email": "cancerclinicaltrials@cumc.columbia.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Brian Henick, MD",
                    "affiliation": "Assistant Professor of Medicine",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Montefiore Health Center",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Balazs Halmos, MD",
                            "role": "CONTACT",
                            "email": "bahalmos@montefiore.org"
                        },
                        {
                            "name": "Balazs Halmos, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Enrico Castellucci, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Mount Sinai School of Medicine",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rajwanth Veluswamy, MD",
                            "role": "CONTACT",
                            "phone": "212-824-8580",
                            "email": "rajwanth.veluswamy@mssm.edu"
                        },
                        {
                            "name": "Rajwanth Veluswamy, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Bailey Gleason Fitzgerald, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "NYU Medical Center",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Vamsidhar Velcheti, MD",
                            "role": "CONTACT",
                            "email": "vamsidhar.velcheti@nyulangone.org"
                        },
                        {
                            "name": "Vamsidhar Velcheti, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Salman Punekar, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brian Henick, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Catherine Shu, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Benjamin Herzberg, MD",
                            "role": "SUB_INVESTIGATOR"
                        },
                        {
                            "name": "Brain Henick, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "31562796",
                    "type": "BACKGROUND",
                    "citation": "Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28."
                },
                {
                    "pmid": "29658856",
                    "type": "BACKGROUND",
                    "citation": "Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16."
                },
                {
                    "pmid": "33476593",
                    "type": "BACKGROUND",
                    "citation": "Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Perol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Erratum In: Lancet Oncol. 2021 Mar;22(3):e92. doi: 10.1016/S1470-2045(21)00082-6."
                },
                {
                    "pmid": "27718847",
                    "type": "BACKGROUND",
                    "citation": "Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8."
                },
                {
                    "pmid": "26712084",
                    "type": "BACKGROUND",
                    "citation": "Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19."
                },
                {
                    "pmid": "32997907",
                    "type": "BACKGROUND",
                    "citation": "Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Ozguroglu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346."
                },
                {
                    "pmid": "31122901",
                    "type": "BACKGROUND",
                    "citation": "West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20."
                },
                {
                    "pmid": "27979383",
                    "type": "BACKGROUND",
                    "citation": "Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13. Erratum In: Lancet. 2017 Apr 8;389(10077):e5. doi: 10.1016/S0140-6736(17)30904-2."
                },
                {
                    "pmid": "28885881",
                    "type": "BACKGROUND",
                    "citation": "Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Ozguroglu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8."
                },
                {
                    "pmid": "26412456",
                    "type": "BACKGROUND",
                    "citation": "Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27."
                },
                {
                    "pmid": "31050774",
                    "type": "BACKGROUND",
                    "citation": "Haslam A, Prasad V. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019 May 3;2(5):e192535. doi: 10.1001/jamanetworkopen.2019.2535."
                },
                {
                    "pmid": "28960263",
                    "type": "BACKGROUND",
                    "citation": "Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28."
                },
                {
                    "pmid": "31801636",
                    "type": "BACKGROUND",
                    "citation": "Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S, Guo Y, Cai S, Wang Y, Li J. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer. 2019 Dec 4;7(1):341. doi: 10.1186/s40425-019-0779-6. Erratum In: J Immunother Cancer. 2020 Jul;8(2):e0779-6corr1. doi: 10.1136/jitc-2020-0779-6corr1."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "Reynolds KL, Cohen JV, Ryan DP, Hochberg EP, Dougan M, Thomas M, Guidon A, Channick C, Chen ST, Schoenfeld S, Sise M, Leaf R, Neilan TG, Chu JN, Hur C, Murciano-Goroff Y, Villani AC, Nasrallah M, Sullivan RJ, Bardia A. Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance. Journal of Clinical Oncology. 2018;36(15_suppl):3096-. doi: 10.1200/JCO.2018.36.15_suppl.3096."
                },
                {
                    "pmid": "32306958",
                    "type": "BACKGROUND",
                    "citation": "Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020 Apr 20;18(1):87. doi: 10.1186/s12916-020-01549-2."
                },
                {
                    "pmid": "31730012",
                    "type": "BACKGROUND",
                    "citation": "Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-019-0805-8."
                },
                {
                    "pmid": "33119034",
                    "type": "BACKGROUND",
                    "citation": "Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol. 2020 Dec 1;6(12):1952-1956. doi: 10.1001/jamaoncol.2020.5012."
                },
                {
                    "pmid": "31182061",
                    "type": "BACKGROUND",
                    "citation": "Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer. 2019 Jun 10;19(1):558. doi: 10.1186/s12885-019-5701-6."
                },
                {
                    "pmid": "31092901",
                    "type": "BACKGROUND",
                    "citation": "Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0."
                },
                {
                    "pmid": "33830825",
                    "type": "BACKGROUND",
                    "citation": "Osarogiagbon RU, Sineshaw HM, Unger JM, Acuna-Villaorduna A, Goel S. Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-13. doi: 10.1200/EDBK_323523."
                },
                {
                    "pmid": "26644527",
                    "type": "BACKGROUND",
                    "citation": "Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7. Erratum In: J Clin Oncol. 2016 Jun 20;34(18):2198. doi: 10.1200/JCO.2016.68.4555. J Clin Oncol. 2019 Feb 20;37(6):528. doi: 10.1200/JCO.19.00057."
                },
                {
                    "pmid": "24711559",
                    "type": "BACKGROUND",
                    "citation": "Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, MacGillivray S. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014 May 10;32(14):1480-501. doi: 10.1200/JCO.2013.53.5948. Epub 2014 Apr 7."
                },
                {
                    "pmid": "30667494",
                    "type": "BACKGROUND",
                    "citation": "Denis F, Basch E, Septans AL, Bennouna J, Urban T, Dueck AC, Letellier C. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer. JAMA. 2019 Jan 22;321(3):306-307. doi: 10.1001/jama.2018.18085."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry: core patient-reported outcomes in cancer clinical trials. 2021 [cited 2021 6 August]. Available from: https://www.fda.gov/media/149994/download."
                },
                {
                    "pmid": "33146385",
                    "type": "BACKGROUND",
                    "citation": "Safa H, Tamil M, Spiess PE, Manley B, Pow-Sang J, Gilbert SM, Safa F, Gonzalez BD, Oswald LB, Semaan A, Diab A, Chahoud J. Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review. J Natl Cancer Inst. 2021 May 4;113(5):532-542. doi: 10.1093/jnci/djaa174."
                },
                {
                    "pmid": "34244760",
                    "type": "BACKGROUND",
                    "citation": "Sisodia RC, Rodriguez JA, Sequist TD. Digital disparities: lessons learned from a patient reported outcomes program during the COVID-19 pandemic. J Am Med Inform Assoc. 2021 Sep 18;28(10):2265-2268. doi: 10.1093/jamia/ocab138."
                },
                {
                    "pmid": "33781441",
                    "type": "BACKGROUND",
                    "citation": "Gadgeel SM. Patient-Reported Outcomes in the Era of Immunotherapy Trials. J Thorac Oncol. 2021 Apr;16(4):516-518. doi: 10.1016/j.jtho.2021.02.014. No abstract available."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "WhereWeLiveNYC. Explore Data- Where New Yokers Live 2018 [cited 2021 6 August]. Available from: https://wherewelive.cityofnewyork.us/explore-data/where-new-yorkers-live/."
                },
                {
                    "type": "BACKGROUND",
                    "citation": "NYCHealth. Lung Cancer. 2021 [cited 2021 6 August]. Available from: https://www1.nyc.gov/site/doh/health/health-topics/lung-cancer.page."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "asFound": "Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                }
            ]
        }
    },
    "hasResults": false
}